RxDoctor Payments Data

Vincent Barnhart, MD

Family Medicine · Greencastle, PANPI 1588748941

Payments from drug & device makers

$339in general payments, 2019–2025

Across 23 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$76
  • Novo Nordisk$57
  • Lilly USA, LLC$37
  • Johnson & Johnson$36
  • Boston Scientific$27
  • Pfizer$26
  • plus $81 from 5 others

What the payments were for

  • Food & beverage$339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$339 in reported general payments places this provider in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$133,419
Medicare patients
448
Services billed
1,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban229$179,284
OzempicSemaglutide76$94,675
JardianceEmpagliflozin87$86,381
XareltoRivaroxaban73$75,273
MounjaroTirzepatide50$53,930
TrulicityDulaglutide41$51,806
FarxigaDapagliflozin Propanediol48$34,661
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$31,845
InvokanaCanagliflozin15$24,365
Breo ElliptaFluticasone/Vilanterol36$19,306
MyrbetriqMirabegron22$19,184
JanuviaSitagliptin Phosphate23$18,162
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$14,635
EntrestoSacubitril/Valsartan17$11,956
Atorvastatin Calcium818$8,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$179,284229 claims
Lilly USA, LLCMounjaro, Trulicity$37$105,73791 claims
Johnson & JohnsonXarelto, Invokana$36$99,63888 claims
Novo NordiskOzempic$57$94,67576 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$13$65,78698 claims
MerckJanuvia$22$18,16223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Greencastle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →